Clinical trials · Raleigh–Durham, NC
Chronic Lymphocytic Leukemia clinical trials in Raleigh–Durham
We’re tracking 25 recruiting chronic lymphocytic leukemia studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Morrisville, North CarolinaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Cary, North CarolinaAges 40–75 - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Durham, North CarolinaAges 18 years+ - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Durham, North CarolinaAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Durham, North CarolinaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Durham, North CarolinaAges 18 years+ - NCT04704323RecruitingPhase 1
CAP-100 drug study for hard-to-treat CLL after prior treatments
This early-phase (Phase 1) study tests CAP-100 in adults with CLL or SLL that has come back or did not respond to at least two previous treatments. The goal is to see how the drug works and whether it is safe enough to keep studying.
Durham, North CarolinaAges 18 years+ - NCT06520098RecruitingPhase 2
BTK inhibitor with or without venetoclax for CLL/SLL
This trial tests whether adding venetoclax to your current BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) works better than taking the BTK inhibitor alone. It's for veterans with CLL or SLL who have been on a BTK inhibitor for at least six months and have not had their disease get worse on that therapy.
Durham, North CarolinaAges 18–80 - NCT06876662RecruitingPhase 4
Continuing pirtobrutinib for CLL and lymphoma patients
This trial continues to give pirtobrutinib to people with chronic lymphocytic leukemia or certain other lymphomas who were already in a previous study with this drug. It helps researchers keep track of long-term safety and how well the drug works over time.
Durham, North CarolinaAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Durham, North CarolinaAges 18 years+ - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Durham, North CarolinaAges 65 years+ - NCT07221500RecruitingPhase 2
Study of NX-5948 for advanced CLL or SLL
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Durham, North CarolinaAges 18 years+ - NCT06973187RecruitingPhase 3
Comparing two drugs for CLL or SLL after prior treatment
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
Durham, North CarolinaAges 18 years+ - NCT06876649RecruitingPhase 4
Long-term safety study of Pirtobrutinib
This trial is for people who are already in a Lilly study taking pirtobrutinib. It looks at the long-term safety of the drug by continuing to monitor you.
Durham, North CarolinaAges 18 years+ - NCT07024706RecruitingPhase 2
Study of acalabrutinib plus venetoclax for relapsed CLL
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Durham, North CarolinaAges 18–130 - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Durham, North CarolinaAges 18 years+ - NCT06860880Recruiting
Personalized program to fight cancer-related fatigue
This trial tests a personalized supportive care program that combines exercise, nutrition, and coaching to help reduce fatigue in people with certain slow-growing lymphomas. It aims to improve energy and quality of life.
Chapel Hill, North CarolinaAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Chapel Hill, North CarolinaAges 13–90 - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Chapel Hill, North CarolinaAges 18–66 - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT07061951RecruitingPhase 2
Mirdametinib for relapsed or refractory CLL or SLL
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT06043674RecruitingPhase 2
Glofitamab alone or with other drugs for Richter's transformation
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
Chapel Hill, North CarolinaAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chapel Hill, North CarolinaAges 13 years+
Hear when a new Chronic Lymphocytic Leukemia trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Chronic Lymphocytic Leukemia trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting chronic lymphocytic leukemia studies listed above.
- Duke University Medical Center · 7 studies
- University of North Carolina at Chapel Hill · 7 studies
- Duke University · 5 studies
- Durham VA Medical Center · 3 studies
- UNC Lineberger Comprehensive Cancer Center · 3 studies
- GC2202 Decentralized Study Site 114
- North Carolina Basnight Cancer Hospital
- Research Site
What taking part in a chronic lymphocytic leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting chronic lymphocytic leukemia studies in North Carolina.
Common questions
- Are there chronic lymphocytic leukemia clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 25 recruiting chronic lymphocytic leukemia studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic lymphocytic leukemia study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic lymphocytic leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic lymphocytic leukemia studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.